Outcomes based on histopathologic response to preoperative chemotherapy in children with bilateral Wilms tumor: A prospective study (COG AREN0534).

Autor: Chintagumpala MM; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas., Perlman EJ; Department of Pathology, Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois., Tornwall B; Department of Biostatistics, College of Public Health & Health Professions and College of Medicine, University of Florida, Gainesville, Florida., Chi YY; Cancer and Blood Disease Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California., Kim Y; Merck Research Laboratories, Merck & Company Inc, Rahway, New Jersey., Hoffer FA; Department of Radiology, Fred Hutchison Cancer Center, University of Washington, Seattle, Washington., Kalapurakal JA; Department of Radiation Oncology, Northwestern Memorial Hospital, Northwestern University, Chicago, Illinois., Warwick AB; Department of Pediatrics, Uniformed Services University, Walter Reed National Military Medical Center, Washington, DC., Shamberger RC; Department of Surgery, Boston Children's Hospital and Dana Farber Cancer Center, Boston, Massachusetts., Khanna G; School of Medicine, Washington University of St Louis, St Louis, Missouri., Hamilton TE; Department of Surgery, Boston Children's Hospital and Dana Farber Cancer Center, Boston, Massachusetts., Gow KW; Department of Surgery, University of Washington, Seattle, Washington., Paulino AC; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Gratias EJ; Children's Oncology Group, Philadelphia, Pennsylvania., Mullen EA; Department of Surgery, Boston Children's Hospital and Dana Farber Cancer Center, Boston, Massachusetts., Geller JI; Division of Hematology/Oncology, Cincinnati Children's Hospital, Cincinnati, Ohio., Fernandez CV; Pediatrics and Bioethics, IWK Health Center, Halifax, Nova Scotia, Canada., Ritchey ML; Department of Urology, Phoenix Children's Hospital, Phoenix, Arizona., Grundy PE; Department of Pediatrics and Oncology, University of Alberta Children's Hospital, Edmonton, Alberta, Canada., Dome JS; Pediatric Surgery, Children's National Hospital and George Washington University School of Medicine and Health Sciences, Washington, DC., Ehrlich PF; Section of Pediatric Surgery, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, Michigan.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2022 Jul 01; Vol. 128 (13), pp. 2493-2503. Date of Electronic Publication: 2022 Apr 05.
DOI: 10.1002/cncr.34219
Abstrakt: Background: An objective of the Children's Oncology Group AREN0534 Study was to improve the survival of patients with bilateral Wilms tumors (BWT) by using preoperative chemotherapy of limited duration and tailoring postoperative therapy based on histopathologic response. The authors report outcomes based on postoperative histopathologic responses.
Methods: Patients with BWT received treatment with vincristine, dactinomycin, and doxorubicin for 6 or 12 weeks followed by surgery. Postoperative therapy was prescribed based on the highest risk tumor according to the International Society of Pediatric Oncology classification and the Children's Oncology Group staging system.
Results: Analyses were performed on data from 180 evaluable children. The 4-year event-free survival (EFS) and overall survival (OS) rates were 81% (95% CI, 74%-87%) and 95% (95% CI, 91%-99%), respectively. Seven patients who had completely necrotic tumors had a 4-year EFS rate of 100%. Of 118 patients who had tumors with intermediate-risk histopathology, the 4-year EFS and OS rates were 82% (95% CI, 74%-90%) and 97% (95% CI, 94%-100%), respectively. Fourteen patients who had blastemal-type tumors had 4-year EFS and OS rates of 79% (95% CI, 56%-100%) and 93% (95% CI, 79%-100%), respectively. Eighteen patients who had diffuse anaplasia had 4-year EFS and OS rates of 61% (95% CI, 35%-88%) and 72% (95% CI, 47%-97%), respectively; and the 4-year EFS and OS rates of 7 patients who had focal anaplasia were 71% (95% CI, 38%-100%) and 100%, respectively. There was no difference in the outcomes of patients who had different histopathologic subtypes within the intermediate-risk group (P = .54).
Conclusions: A risk-adapted treatment approach for BWT results in excellent outcomes. This approach was not successful in improving the outcome of patients who had diffuse anaplasia.
(© 2022 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: